Clinical trial
Phase 3 Randomized Trial of DFP-10917 vs Non-Intensive Reinduction (LoDAC, Azacitidine, Decitabine, Venetoclax Combination Regimens) or Intensive Reinduction (High & Intermediate Dose Cytarabine Regimens) for Acute Myelogenous Leukemia Patients in Second, Third, or Fourth Salvage
NCT03926624 is registered in ClinicalTrials.gov with Delta-Fly Pharma, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase 3 Randomized Trial of DFP-10917 vs Non-Intensive Reinduction (LoDAC, Azacitidine, Decitabine, Venetoclax Combination Regimens) or Intensive Reinduction (High & Intermediate Dose Cytarabine Regimens) for Acute Myelogenous Leukemia Patients in Second, Third, or Fourth Salvage
- Lead sponsor
- Delta-Fly Pharma, Inc.
- Phase
- Phase 3
- Overall status
- Terminated
- Start date
- November 22, 2019
- Completion date
- January 7, 2026
- Enrollment
- 167 (actual)
- Sites
- 39
Conditions
As the registry lists them; a condition with its own page is linked.